TIZONA THERAPEUTICS
The company is establishing collaborations with its scientific founders “to better understand whether regulatory T cells play a more prominent role in certain tumors,” he added. Although research suggests that Tregs cells play a more prominent role in creating immunosuppression in the microenvironment in some tumor types than others, “quite honestly, the data are lacking. One of the ways we’re going to differentiate the company is to understand that relationship better.
TIZONA THERAPEUTICS
Industry:
Biotechnology Medical Therapeutics
Founded:
2014-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.tizonatx.com
Total Employee:
11+
Status:
Active
Total Funding:
370 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Google Tag Manager Google Analytics Google Maps LetsEncrypt SSL By Default Global Site Tag HSTS
Similar Organizations
Amber Therapeutics
Amber Therapeutics develops the next-generation of bioelectrical therapies.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
D2M Biotherapeutics
D2M Biotherapeutics focuses on the development of novel immunotherapeutics.
Mana Therapeutics
Next-Generation Immunotherapies
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
TATTOOX
Tattoox is the largest tattoo community
Current Advisors List
Advisor
Board_member
Board_member
2020-08-01
Board_member
2020-11-01
Board_member
Board_member
2016-02-01
Board_member
Board_member
Current Employees Featured
John Corbin CTO @ Tizona Therapeutics
CTO
Christine O’Brien CEO @ Tizona Therapeutics
CEO
Courtney Beers CSO @ Tizona Therapeutics
CSO
Shelly Pinto Vice President of Finance and Controller @ Tizona Therapeutics
Vice President of Finance and Controller
Founder
Investors List
Gilead Sciences
Gilead Sciences investment in Corporate Round - Tizona Therapeutics
InterWest Partners
InterWest Partners investment in Series B - Tizona Therapeutics
Astellas Venture Management
Astellas Venture Management investment in Series B - Tizona Therapeutics
Abingworth
Abingworth investment in Series B - Tizona Therapeutics
Lightstone Ventures
Lightstone Ventures investment in Series B - Tizona Therapeutics
MPM Capital
MPM Capital investment in Series B - Tizona Therapeutics
Canaan Partners
Canaan Partners investment in Series B - Tizona Therapeutics
Amgen Ventures
Amgen Ventures investment in Series B - Tizona Therapeutics
InterWest Partners
InterWest Partners investment in Series A - Tizona Therapeutics
Astellas Venture Management
Astellas Venture Management investment in Series A - Tizona Therapeutics
Official Site Inspections
http://www.tizonatx.com Semrush global rank: 6.69 M Semrush visits lastest month: 1.05 K
- Host name: ec2-34-192-255-123.compute-1.amazonaws.com
- IP address: 34.192.255.123
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Tizona Therapeutics"
Leadership | Board or Directors | Investors | Tizona …
O’Brien joined Tizona in 2015 and served most recently as the Chief Operating Officer. During her time at Tizona, she has led the cross-functional execution of the company’s portfolio and operating plan during a time when the …See details»
Tizona Therapeutics | Improving outcomes for people with cancer
May 15, 2024 Recent News. October 31, 2024 Tizona Therapeutics Announces Expansion of Phase 1b Clinical Trial to Evaluate TTX-080 in Combination with EGFR Inhibitor Cetuximab …See details»
Tizona Therapeutics - Crunchbase Company Profile & Funding
Contact Email info@tizonatx.com The company is establishing collaborations with its scientific founders “to better understand whether regulatory T cells play a more prominent role in certain …See details»
Tizona Therapeutics, Inc. | LinkedIn
Tizona Therapeutics, Inc. | 4,767 followers on LinkedIn. Harnessing the power of the immune system to develop treatments for cancer. | Tizona Therapeutics, Inc., is an immunology company ...See details»
Tizona Therapeutics Company Profile | Management and
Tizona Therapeutics Profile and History . Tizona is a privately held, clinical-stage immunotherapy company that develops first-in-class medicines to deliver transformational benefits for people …See details»
Tizona Therapeutics - LifeScienceHistory.com
Www.tizonatx.com. 4000 Shoreline Court, Suite 200. South San Francisco, CA 94080. Company Info Phone (650) 383-0800 Year Established 2014. Contacts Christine OﾒBrien CEO Erin …See details»
Tizona Therapeutics 2025 Company Profile: Valuation ... - PitchBook
Information on valuation, funding, cap tables, investors, and executives for Tizona Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Tizona Therapeutics CEO and Key Executive Team | Craft.co
Tizona Therapeutics's Chief Scientific Officer is Courtney Beers. Other executives include Christine O'Brien, Chief Executive Officer, Director; Pankaj Bhargava, Director and 4 others. …See details»
Tizona Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Tizona Therapeutics, Inc. of South San Francisco, CA. Get the latest business insights from Dun & …See details»
Tizona Therapeutics | Improving outcomes for people with cancer
Recent News. May 15, 2024 Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024. …See details»
Tizona Appoints Christine O’Brien as Chief Executive
Sep 15, 2020 O’Brien joined Tizona in 2015 and led the cross-functional execution of the company’s portfolio and operating plan during a time when the organization advanced two, …See details»
Tizona Therapeutics - Overview, News & Similar companies
Oct 13, 2021 www.tizonatx.com. Revenue $5.6 Million. Industry Business Services General Business Services . Recent News & Media. Tizona Therapeutics Presents Phase 1b TTX-080 …See details»
Working At Tizona Therapeutics: Company Overview and Culture
Mar 14, 2024 www.tizonatx.com. Organization Type. Private. CEO. Christine O’Brien. Social Media. Tizona Therapeutics is an immunology company harnessing the power of the immune …See details»
Press Release for Tizona Therapeutics
Sep 15, 2020 Tizona Appoints Christine O’Brien as Chief Executive Officer – Transaction with Gilead Sciences Closed – – Tizona Advances TTX-080, a Novel Anti-HLA-G Antibody, with …See details»
Tizona Appoints Christine O’Brien as Chief Executive Officer
Sep 15, 2020 SOUTH SAN FRANCISCO, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a clinical stage, privately held company developing first-in-class cancer …See details»
Tizona Therapeutics - Craft
Tizona Therapeutics is an immunology company which develops treatments for cancer and autoimmune diseases. Its main products are anti-ccr4 antibody for the treatment of cancer and …See details»
Tizona Therapeutics - workinbiotech.com
Tizona Therapeutics is harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Cancers use various strategies to evade detection by the …See details»
Join Team Tizona | Job Opportunities | Tizona Therapeutics
Culture and Benefits Striving to be the Best. The best teams are built by hiring the best people. Tizona cultivates a science-driven, creative, open, honest, optimistic and respectful corporate …See details»
Latest News and Press Releases from Tizona Therapeutics
Tizona News. October 31, 2024 Tizona Therapeutics Announces Expansion of Phase 1b Clinical Trial to Evaluate TTX-080 in Combination with EGFR Inhibitor Cetuximab and Chemotherapy …See details»
Press Release for Tizona Therapeutics
Tizona’s lead drug candidate, an anti-CCR4 monoclonal antibody, is expected to enter the clinic in 2017. For more information, visit www.tizonatx.com. Media Contact. Lori Melançon …See details»